The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Editorial
PreviousPrevious
Volume 346:1740-1742 May 30, 2002 Number 22
NextNext

Can We Change the Course of Beta-Cell Destruction in Type 1 Diabetes?

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Commentary
-Letters

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
-Related Article
 by Diabetes Prevention Trial–Type 1 Diabetes Study Group
-Related Article
 by Herold, K. C.
-PubMed Citation
Imagine a nephrologist with no biopsy needle, no imaging techniques, no serum creatinine measurement — a nephrologist whose patients need dialysis when they first present for care. This is the predicament of the diabetologist, whose patients with type 1 diabetes routinely present with end-stage pancreatic beta-cell failure and must be informed that they have an incurable condition requiring lifelong rear-guard action against vascular complications. The future may not be so bleak, however. The natural history of the process leading to type 1 diabetes has been charted by prospective studies; robust predictive strategies are in place; and trials of a variety . . . [Full Text of this Article]

References


Related Letters:

Anti-CD3 Monoclonal Antibody in New-Onset Type 1 Diabetes Mellitus
Killestein J., Herold K. C., Bluestone J. A.
Extract | Full Text | PDF  
N Engl J Med 2002; 347:1116-1117, Oct 3, 2002. Correspondence

This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.